Elicio Therapeutics, Inc. (ELTX) Research

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

Market snapshot

Symbol
ELTX
Price
$3.85
Day change
-18.26%
Market cap
$73.5M
P/E ratio
-1.74x
52-week range
2.66-16
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$17.00

Recent news

  • Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug

    Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is up on Wednesday as the company reported promising clinical observations regarding its ELI-002 7P treatment.

  • Elicio Therapeutics Pancreatic Cancer Study Disappoints

    Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is trading lower on Monday after disappointing results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) following standard locoregional treatment.

  • Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal

    Elicio Therapeutics shares fell about 73% in early trading on Monday after the biotech firm's pancreatic cancer therapy failed to significantly extend the time ​patients lived without their disease returning, missing the main goal of ‌a mid-stage study.

Peer companies

  • Actuate Therapeutics Inc (ACTU)
  • Applied Therapeutics, Inc. (APLT)
  • Corbus Pharmaceuticals Holdings, Inc. (CRBP)
  • Cardiff Oncology, Inc. (CRDF)
  • Milestone Pharmaceuticals Inc. (MIST)
  • Molecular Partners AG (MOLN)
  • Nkarta, Inc. (NKTX)
  • PepGen Inc. (PEPG)

Recent insider activity

  • Connelly Robert — A-Award (147200 shares) on 2026-02-02
  • Connelly Robert — A-Award (73600 shares) on 2026-02-02
  • Shah Preetam — A-Award (47900 shares) on 2026-02-02
  • Shah Preetam — A-Award (24000 shares) on 2026-02-02
  • DeMuth Peter — A-Award (41600 shares) on 2026-02-02

Open Elicio Therapeutics, Inc. (ELTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.